 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 May 1996 | Volume 124 Issue 9 | Pages 785-791
Objective: To determine whether azithromycin or amoxicillin is more efficacious for the treatment of erythema migrans skin lesions, which are characteristic of Lyme disease.
Design: Randomized, double-blind, double-dummy, multicenter study. Acute manifestations and sequelae were assessed using a standardized format. Baseline clinical characteristics and response were correlated with serologic results. Patients were followed for 180 days.
Setting: 12 outpatient centers in eight states.
Patients: 246 adult patients with erythema migrans lesions at least 5 cm in diameter were enrolled and were stratified by the presence of flu-like symptoms (such as fever, chills, headache, malaise, fatigue, arthralgias, and myalgias) before randomization.
Intervention: Oral treatment with either amoxicillin, 500 mg three times daily for 20 days, or azithromycin, 500 mg once daily for 7 days. Patients who received azithromycin also received a dummy placebo so that the dosing schedules were identical.
Results: Of 217 evaluable patients, those treated with amoxicillin were significantly more likely than those treated with azithromycin to achieve complete resolution of disease at day 20, the end of therapy (88% compared with 76%; P = 0.024). More azithromycin recipients (16%) than amoxicillin recipients (4%) had relapse (P = 0.005). A partial response at day 20 was highly predictive of relapse (27% of partial responders had relapse compared with 6% of complete responders; P < 0.001). For patients treated with azithromycin, development of an antibody response increased the possibility of achieving a complete response (81% of seropositive patients achieved a complete response compared with 60% of seronegative patients; P = 0.043). Patients with multiple erythema migrans lesions were more likely than patients with single erythema migrans lesions (P < 0.001) to have a positive antibody titer at baseline (63% compared with 17% for IgM; 39% compared with 16% for IgG). Fifty-seven percent of patients who had relapse were seronegative at the time of relapse.
Conclusions: A 20-day course of amoxicillin was found to be an effective therapeutic regimen for erythema migrans. Most patients were seronegative for Borrelia burgdorferi at the time of presentation with erythema migrans (65%) and at the time of relapse (57%).
Author and Article Information
From State University of New York at Stony Brook, Stony Brook, New York; University of Minnesota, Minneapolis, Minnesota; Kaiser Permanente, Rocky Hill, Connecticut; Yale University, New Haven, Connecticut; Family Physician's Group, Cape Girardeau, Missouri; and Pfizer Central Research, Groton, Connecticut.
ARTICLE
Azithromycin Compared with Amoxicillin in the Treatment of Erythema Migrans: A Double-Blind, Randomized, Controlled Trial
Acknowledgments: The authors thank the following persons and institutions for their participation in this trial: R. Nadelman and G. Wormser (Westchester Medical Center, Valhalla, New York); J. Melski (Marshfield Clinic, Marshfield, Wisconsin); T. Rush (Briarcliff Manor, New York); L. Sigal (Robert Wood Johnson Medical School, New Brunswick, New Jersey); R. Messner (University of Minnesota, Minneapolis, Minnesota); P. Paparone (Absecon, New Jersey); E. Jost (Westerly Hospital, Westerley, Rhode Island); and J. Katzel (Ukiah, California).
Grant Support: In part by a grant from Pfizer Central Research, Groton, Connecticut. Dr. Gadgil collaborated with the Project Leaders, Drs. Luft and Dattwyler, in designing the trial. Pfizer Central Research provided data management and biostatistical support. The interpretation and presentation of the results were the responsibility of the Project Leaders. Drs. Luft and Dattwyler and Ms. Bosler were supported in part by grants from New York State and the National Institutes of Health (AI32454).
Requests for Reprints: Benjamin J. Luft, MD, Department of Medicine, HSC T-16, State University of New York at Stony Brook, Stony Brook, NY 11794-8160.
Current Author Addresses: Dr. Luft and Ms. Bosler: Department of Medicine, HSC T-16, Room 020, State University of New York at Stony Brook, Stony Brook, NY 11794.
This article has been cited by other articles:
|
|
 |
|
  C. D. Tibbles and J. A. Edlow Does This Patient Have Erythema Migrans? JAMA, June 20, 2007; 297(23): 2617 - 2627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. Wormser Clinical practice. Early Lyme disease. N. Engl. J. Med., June 29, 2006; 354(26): 2794 - 2801. [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. Wormser, D. McKenna, J. Carlin, R. B. Nadelman, L. F. Cavaliere, D. Holmgren, D. W. Byrne, and J. Nowakowski Brief Communication: Hematogenous Dissemination in Early Lyme Disease Ann Intern Med, May 3, 2005; 142(9): 751 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Dinser, M C Jendro, S Schnarr, and H Zeidler Antibiotic treatment of Lyme borreliosis: what is the evidence? Ann Rheum Dis, April 1, 2005; 64(4): 519 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-P. Hunfeld, T. A. Wichelhaus, R. Rodel, G. Acker, V. Brade, and P. Kraiczy Comparison of In Vitro Activities of Ketolides, Macrolides, and an Azalide against the Spirochete Borrelia burgdorferi Antimicrob. Agents Chemother., January 1, 2004; 48(1): 344 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Philipp, A. R. Marques, P. T. Fawcett, L. G. Dally, and D. S. Martin C6 Test as an Indicator of Therapy Outcome for Patients with Localized or Disseminated Lyme Borreliosis J. Clin. Microbiol., November 1, 2003; 41(11): 4955 - 4960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Wormser, R. Ramanathan, J. Nowakowski, D. McKenna, D. Holmgren, P. Visintainer, R. Dornbush, B. Singh, and R. B. Nadelman Duration of Antibiotic Therapy for Early Lyme Disease: A Randomized, Double-Blind, Placebo-Controlled Trial Ann Intern Med, May 6, 2003; 138(9): 697 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Steere Duration of Antibiotic Therapy for Lyme Disease Ann Intern Med, May 6, 2003; 138(9): 761 - 762. [Full Text] [PDF]
|
|
|
|
|
|
D. Liveris, G. Wang, G. Girao, D. W. Byrne, J. Nowakowski, D. McKenna, R. Nadelman, G. P. Wormser, and I. Schwartz Quantitative Detection of Borrelia burgdorferi in 2-Millimeter Skin Samples of Erythema Migrans Lesions: Correlation of Results with Clinical and Laboratory Findings J. Clin. Microbiol., April 1, 2002; 40(4): 1249 - 1253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Smith, R. T. Schoen, D. W. Rahn, V. K. Sikand, J. Nowakowski, D. L. Parenti, M. S. Holman, D. H. Persing, and A. C. Steere Clinical Characteristics and Treatment Outcome of Early Lyme Disease in Patients with Microbiologically Confirmed Erythema Migrans Ann Intern Med, March 19, 2002; 136(6): 421 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Nadelman and G. P. Wormser Recognition and Treatment of Erythema Migrans: Are We Off Target? Ann Intern Med, March 19, 2002; 136(6): 477 - 479. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Nowakowski, D. McKenna, R. B. Nadelman, D. Cooper, S. Bittker, D. Holmgren, C. Pavia, R. C. Johnson, and G. P. Wormser Failure of Treatment With Cephalexin for Lyme Disease Arch Fam Med, June 1, 2000; 9(6): 563 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Strle, R. B. Nadelman, J. Cimperman, J. Nowakowski, R. N. Picken, I. Schwartz, V. Maraspin, M. E. Aguero-Rosenfeld, S. Varde, S. Lotric-Furlan, et al. Comparison of Culture-Confirmed Erythema Migrans Caused by Borrelia burgdorferi sensu stricto in New York State and by Borrelia afzelii in Slovenia Ann Intern Med, January 5, 1999; 130(1): 32 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Masters, K. B. Kirkland, and D. T. Dennis Erythema Migrans in the South Arch Intern Med, October 26, 1998; 158(19): 2162 - 2165. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Masters, S. Granter, P. Duray, and P. Cordes Physician-Diagnosed Erythema Migrans and Erythema Migrans-like Rashes Following Lone Star Tick Bites Arch Dermatol, August 1, 1998; 134(8): 955 - 960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Ravyn, J. L. Goodman, C. B. Kodner, D. K. Westad, L. A. Coleman, S. M. Engstrom, C. M. Nelson, and R. C. Johnson Immunodiagnosis of Human Granulocytic Ehrlichiosis by Using Culture-Derived Human Isolates J. Clin. Microbiol., June 1, 1998; 36(6): 1480 - 1488. [Abstract] [Full Text]
|
|
|
|
 |
|
 Azithromycin vs. Amoxicillin for Erythema Migrans Journal Watch Dermatology, July 1, 1996; 1996(701): 11 - 11. [Full Text]
|
|
|
|
|
|
Amoxicillin for Erythema Migrans in Presumed Lyme Disease Journal Watch Dermatology, June 1, 1996; 1996(601): 18 - 18. [Full Text]
|
|
|
|
 |
|
 AMOXICILLIN FOR ERYTHEMA MIGRANS IN PRESUMED LYME DISEASE Journal Watch (General), May 14, 1996; 1996(514): 3 - 3. [Full Text]
|
|
Article
